Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30 mai 2024 13h41 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Bionano Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow
30 mai 2024 08h00 HE
|
Bionano Genomics
Bionano announces a record 39 scientific presentations and posters highlighting optical genome mapping at two upcoming global cytogenetics conferences.
Global Rare Disease Diagnostics Market is Projected to Hit USD 88,969.27 Million by 2032, With a CAGR of 9.2% From 2024 to 2032- Report by Polaris Market Research (PMR)
23 mai 2024 09h30 HE
|
Polaris Market Research & Consulting LLP
New York, May 23, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global Rare Disease Diagnostics Market size is projected to grow from USD 40,227.42 million in 2023 to USD 88,969.27 million by 2032,...
Fc and Glycoengineered Antibodies Research 2024: Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships - Long-term Forecasts to 2035
22 mai 2024 04h47 HE
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy,...
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
16 mai 2024 17h29 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
Mathew Hall, Sarcoidosis Warrior, Takes on Iron Man 70.3 Chattanooga to Raise Awareness and Support for Sarcoidosis
15 mai 2024 10h24 HE
|
Foundation for Sarcoidosis Research
Sarcoidosis warrior takes on Iron Man competition
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
07 mai 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01 mai 2024 08h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
30 avr. 2024 09h00 HE
|
Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
30 avr. 2024 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...